Research Activity – Page 4

AstraZeneca’s dual-targeting CAR-T AZD0120 shows similar response rates in Western and Chinese patients

2 months ago talkbio0Tagged AstraZeneca, Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, AZD0120, BCMAxCD19, CAR-T, China, Clinical Trials, dual-targeting CAR-T, DURGA-1, Frequency of Responses, Multiple Myeloma, Western patients

AstraZeneca; AZD0120; GC012F; dual-targeting CAR-T; BCMAxCD19; multiple myeloma; DURGA-1; China; Western patients; response rate; clinical trial; CAR-T

FDA names Tracy Beth Heg as acting CDER chief

2 months ago talkbio0Tagged CDER, Center for Drug Evaluation, Chief, COVID19 (disease), Drug Regulations, Leadership, research, Tracy Beth Heg, U.S. Food and Drug Administration, United States Food and Drug Administration, Vaccine Safety

Tracy Beth Heg; acting CDER chief; FDA leadership; Center for Drug Evaluation and Research; COVID-19 vaccine safety; drug regulation; U.S. Food and Drug Administration

Former FDA Chiefs Criticize Proposed Vaccine Policy Changes at ACIP Meeting

2 months ago talkbio0Tagged * New England Journal of Medicine*., ACIP, Centers for Disease Control and Prevention (U.S.), Changing, commissioners, COVID19 (disease), Policy, research, Senator Bill Cassidy, United States Food and Drug Administration, vaccine safety regulation, Vaccines, Vinay Prasad ; Center for Biologics Evaluation

former FDA commissioners; CDC; ACIP meeting; vaccine policy changes; COVID-19 vaccines; Vinay Prasad; Center for Biologics Evaluation and Research; vaccine safety regulation; Senator Bill Cassidy; New England Journal of Medicine commentary

Bristol Myers Squibb Delays Cobenfy Alzheimer’s Psychosis Trial Readout Due to Site Irregularities

2 months ago talkbio0Tagged ADEPT-2 trial, Alzheimer 's psychosis, Cobenfy, Deferred, Myers Squibb, Phase 3 Clinical Trials, trial site irregularities

Bristol Myers Squibb; Cobenfy; Alzheimer’s psychosis; ADEPT-2 trial; trial site irregularities; Phase III study; delay; 2026

Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery

2 months ago2 months ago talkbio0Tagged Biotechnology, Chief AI Officer, Drug Development, Drug Discovery, Harbour Mice ® technology, Hongjiang Miao, integrated solutions, Nona Biosciences, Shanghai

Nona Biosciences; Hongjiang Miao; Chief AI Officer; AI-Driven Drug Discovery; biotechnology; Shanghai; drug development; Harbour Mice technology; integrated solutions

Capricor Therapeutics Reports Positive Phase 3 HOPE-3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy, Planning FDA Resubmission

2 months ago talkbio0Tagged Capricor Therapeutics, cardiac function preservation, Clinical Trials, deramiocel, HOPE-3 trial, Muscular Dystrophy, Duchenne, Phase 3 clinical trial, regulatory approval pathway, Rejection, United States Food and Drug Administration, upper limb function

Capricor Therapeutics; Deramiocel; Duchenne muscular dystrophy; HOPE-3 trial; Phase 3 clinical trial; FDA rejection; cardiac function preservation; upper limb function; clinical trial results; regulatory approval pathway

Recent Developments on Vinay Prasad’s Leaked FDA Memo, Alzheimer’s Disease Updates, and Next-Gen Obesity Drugs

2 months ago talkbio0Tagged Alzheimer 's disease, Cessation of life, Child, COVID19 (disease), next-generation, Obesity, research, United States Food and Drug Administration, Vaccines, Vinay Prasad FDA memo

Vinay Prasad FDA memo; COVID-19 vaccine deaths children; FDA vaccine approval changes; Alzheimer’s disease research 2025; obesity drugs next generation; COVID-19 vaccine safety controversy; FDA vaccine policy overhaul

Top Drug Regulator Richard Pazdur to Retire from FDA Amid Industry Concerns

2 months ago talkbio0Tagged Center for Drug Evaluation, Drug Regulations, Leadership, Personnel Turnover, research, Retirement, Richard Pazdur, United States Food and Drug Administration

Richard Pazdur; FDA; retirement; Center for Drug Evaluation and Research; drug regulation; Marty Makary; leadership turnover

Imvax Shares Positive Phase 2b Data for IGV-001 Glioblastoma Treatment and Plans FDA Meeting

2 months ago talkbio0Tagged Clinical Trials, Glioblastoma, IGF-1R Antisense Oligodeoxynucleotide-treated Autologous Glioma Cells IGV-001, Immunotherapy, Imvax, meeting, Overall Survival, United States Food and Drug Administration

Imvax; IGV-001; glioblastoma; Phase 2b trial; overall survival; FDA meeting; immunotherapy; clinical trial; glioblastoma treatment

Alkeus Pharmaceuticals Appoints Carlos Quezada-Ruiz as Chief Medical Officer

2 months ago talkbio0Tagged Alkeus, Biological Factors, Carlos Quezada-Ruiz, Chief Medical Officer, Clinical Research, gildeuretinol, Ophthalmology specialty, Retinal Diseases, Stargardt's disease

Alkeus Pharmaceuticals; Carlos Quezada-Ruiz; Chief Medical Officer; Stargardt disease; gildeuretinol; retinal diseases; ophthalmology; clinical research; biopharmaceutical leadership